Logo image
Additional file 2 of Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis
Dataset

Additional file 2 of Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, Maryam Barkhordar, Syed Aon Mehdi Abbas, Morteza Azari, Mohammad Ahmadvand, Zahra Salehi, Shiva Rouzbahani and Mohammad Vaezi
figshare
2024-08-15

Abstract

FOS: Clinical medicine Immunology
Additional file 2: Fig. S1. Forest plot of pooled seropositive rate difference between third and second dose in HSCT patients. Fig. S2. Forest plot of pooled seropositive rate difference between fourth and third dose in HSCT patients. Fig. S3. Forest plot of pooled seropositive rate difference between third and second dose in CAR-T cell patients. Fig. S4. Forest plot of seroconversion after the third dose in HSCT recipients by the interval between transplantation and vaccination initiation. This plot demonstrates higher seroconversion rates among patients with a median interval of more than 12 months from cell therapy to the first dose of immunization. Fig. S5. Forest plot of seroconversion after third dose in HSCT recipients by brand of the mRNA vaccine received.
url
https://doi.org/10.6084/m9.figshare.25750126View
Open
url
https://doi.org/10.6084/m9.figshare.25750126View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image